Finally, anti-tumor activity has been achieved with BCMA-directed or ligand-directed therapeutic agents in both pre-clinical MM models as well as in early phase human clinical trials that include CAR-T cell therapy [17–22]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.